1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Status Epilepticus - Pipeline Review, H1 2016

Status Epilepticus - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 58 pages

Status Epilepticus - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Status Epilepticus - Pipeline Review, H1 2016’, provides an overview of the Status Epilepticus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Status Epilepticus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Status Epilepticus and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Status Epilepticus
- The report reviews pipeline therapeutics for Status Epilepticus by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Status Epilepticus therapeutics and enlists all their major and minor projects
- The report assesses Status Epilepticus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Status Epilepticus

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Status Epilepticus
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Status Epilepticus pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Status Epilepticus - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Status Epilepticus Overview 6
Therapeutics Development 7
Pipeline Products for Status Epilepticus - Overview 7
Pipeline Products for Status Epilepticus - Comparative Analysis 8
Status Epilepticus - Therapeutics under Development by Companies 9
Status Epilepticus - Therapeutics under Investigation by Universities/Institutes 10
Status Epilepticus - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Status Epilepticus - Products under Development by Companies 14
Status Epilepticus - Products under Investigation by Universities/Institutes 15
Status Epilepticus - Companies Involved in Therapeutics Development 16
Marinus Pharmaceuticals, Inc. 16
RODES Inc. 17
Sage Therapeutics, Inc. 18
Status Epilepticus - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 27
AMPX-0079 - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
fosphenytoin sodium - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
ganaxolone - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
SAGE-217 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
SAGE-689 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
sepranolone - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
TG-4155 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Status Epilepticus - Recent Pipeline Updates 38
Status Epilepticus - Dormant Projects 47
Status Epilepticus - Product Development Milestones 48
Featured News and Press Releases 48
Dec 15, 2015: SAGE Updates Guidance for Top-Line Results of Phase 3 STATUS Trial of SAGE-547 48
Dec 02, 2015: SAGE to Present Poster Presentations on SAGE-547 at the American Epilepsy Society 69th Annual Meeting 48
Aug 17, 2015: SAGE Announces First Patient Treated in Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus 49
Aug 06, 2015: SAGE Receives Special Protocol Assessment for Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus 50
Jun 09, 2015: SAGE Therapeutics Announces Positive Top-Line Data in Exploratory Trial of SAGE-547 in Postpartum Depression 50
May 14, 2015: SAGE Therapeutics Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in Super-Refractory Status Epilepticus 51
Apr 22, 2015: Ligand Earns Milestone from SAGE Therapeutics for SAGE-547 53
Apr 20, 2015: SAGE Therapeutics Announces First Patient Treated Under Phase 3 Expanded Access Protocol to Evaluate SAGE-547 in Patients With Super-Refractory Status Epilepticus 54
Apr 09, 2015: SAGE Therapeutics presents preclinical data on SAGE-689 at Upcoming Scientific Conferences 54
Apr 09, 2015: SAGE Therapeutics presents Phase 1/2 clinical trial data on SAGE-547 at Upcoming Scientific Conferences 55
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58

List of Tables
Number of Products under Development for Status Epilepticus, H1 2016 7
Number of Products under Development for Status Epilepticus - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Status Epilepticus - Pipeline by Marinus Pharmaceuticals, Inc., H1 2016 16
Status Epilepticus - Pipeline by RODES Inc., H1 2016 17
Status Epilepticus - Pipeline by Sage Therapeutics, Inc., H1 2016 18
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Stage and Target, H1 2016 21
Number of Products by Stage and Mechanism of Action, H1 2016 23
Number of Products by Stage and Route of Administration, H1 2016 25
Number of Products by Stage and Molecule Type, H1 2016 26
Status Epilepticus Therapeutics - Recent Pipeline Updates, H1 2016 38
Status Epilepticus - Dormant Projects, H1 2016 47

List of Figures
Number of Products under Development for Status Epilepticus, H1 2016 7
Number of Products under Development for Status Epilepticus - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Targets, H1 2016 20
Number of Products by Stage and Targets, H1 2016 20
Number of Products by Mechanism of Actions, H1 2016 22
Number of Products by Stage and Mechanism of Actions, H1 2016 22
Number of Products by Routes of Administration, H1 2016 24
Number of Products by Stage and Routes of Administration, H1 2016 24
Number of Products by Stage and Molecule Types, H1 2016 26

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.